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ABSTRACT  
The veterinary use of antimicrobial drugs in food 
producing animals may result in residues in food, that 
might modify the consumer gut flora. This review 
compares three model systems that maintain a 
complex flora of human origin: (i) human flora 
associated (HFA) continuous flow cultures in 
chemostats, (ii) HFA mice, and (iii) human 
volunteers. The "No Microbial Effect Level" of an 
antibiotic on human flora, measured in one of these 
models, is used to set the acceptable daily intake 
(ADI) for human consumers. Human volunteers trials 
are most relevant to set microbiological ADI, and 
may be considered as the "gold standard". However, 
human trials are very expensive and unethical. HFA 
chemostats are controlled systems, but tetracycline 
ADI calculated from a chemostat study is far above 
result of a human study. HFA mice studies are less 
expensive and better controlled than human trials. 
The tetracycline ADI derived from HFA mice studies 
is close to the ADI directly obtained in human 
volunteers. 
  
Introduction
 The veterinary use of antimicrobial drugs in 
food producing animals may result in antibiotic 
residues in food. The intake of meat, milk or eggs 
containing low levels of antibiotic might modify the 
intestinal microflora of the consumer. Of particular 
concern is the selection of drug resistant bacteria in 
the gut. The microbiological safety of these residues 
is not easy to assess, and many experimental models 
had been proposed and reviewed (1,2). The present 
paper gives a short overview of in vivo model 
systems, and compare three model systems that 
maintain a complex flora of human origin: (i) human 
flora associated (HFA) continuous flow cultures in 
chemostats, (ii) HFA mice, and (iii) human 
volunteers. The aim of these models is to find the no 
microbial effect level (NoMEL) of an antibiotic on 
human flora. This NoMEL value is extrapolated to 
set the acceptable daily intake (ADI) that will not 
produce an adverse effect on the gut flora of a human 
consumer. This paper discusses how ADI can be 
derived from NoMEL, and the pros and cons of the 
three models. 
Microbiological Adverse Effect:  
How may drug residues be harmful to the human 
intestinal microflora?
 Gut flora maintains a "barrier" that prevents 
colonization by, and overgrowth of, unwanted 
bacteria, e.g., drug resistant or pathogenic strains.  
- Drug resistance. Antibiotic residues might favor the 
growth of antibiotic resistant bacteria in the gut. The 
reservoir of resistant genes would thus enlarge, 
increasing the probability that a resistance gene is 
transferred to a pathogen. 
- Pathogens. Antibiotic residues might reduce the 
colonization resistance to pathogenic invaders 
(Salmonella sp., Clostridium difficile, Campylobacter 
sp., Entero-Pathogenic E. coli, Staphylococcus 
aureus, Candida sp.). The overgrowth of these 
pathogens could lead to diarrhea or enterocolitis. 
Salmonella may be more a public health problem 
than Clostridia, which are often found in hospitalized 
patients, because of antibiotic therapy. 
- Other changes. Antibiotics may change some 
bacterial density and/or some bacterial enzymatic 
activity in the gut, with no known clinical 
consequence. Drug residues may even induce 
beneficial changes in the gut; e.g., neomycin can 
decrease the intestinal concentration of toxic 
secondary bile acids (3). 
  
 Antibiotic resistance and pathogen overgrowth 
are probably the only true adverse effects for humans, 
and thus the only relevant endpoints to be assessed 
when testing the effects of a residue on intestinal 
microflora. In addition, the proportion of drug 
resistant bacteria in vivo may be the most sensitive 
endpoint in most studies (4). 
In vivo model systems: humans, conventional 
animals, and HFA mice  
- Human volunteers: Since the inter-subject and day-
to-day variability of the flora is high in humans, trials 
should be randomized, placebo-controlled and 
double-blinded, and should include at least 20 
volunteers per group, treated for more than 20 days 
(1). Each group should be dosed with either (i) a 
placebo, (ii) the tested drug (at leat, two dose levels), 
and (iii) a drug known to change the flora, e.g., 
clindamycin at a dose of 0.6 g/day (positive control) 
(5). The intestinal microflora should be monitored 
daily, and compliance assessed by assaying the drug 
in urine or stools. 
- Conventional animal models: The composition of 
animals' flora is far from the humans'. Rodents have 
no E. coli. Farm animals often have flora with a high 
resistance baseline to antibiotics. Monkeys are very 
expensive and therefore their use as a routine model 
system is not recommended. The flora of dogs is 
different from that of humans, but dog may be an 
acceptable species for this purpose (6). 
- HFA mice: Groups of germ-free mice maintained in 
complete bacteriological isolation in isolators, are 
inoculated by gavage with an anaerobic dilution of 
human stools (1,7). These HFA mice retain a high 
number of dominant anaerobes from the human gut 
flora. This complex flora can thus resist colonization 
by sub-dominant aerobes, drug-resistant and 
pathogenic strains (7,8).  
HFA mice and men:  
How should we extrapolate from a NoMEL to an 
ADI? 
 HFA mice studies can be used to find the oral
dose with no adverse effect on microbiological 
parameters (in vivo NoMEL). To translate the 
NoMEL to an ADI in humans, three different 
approaches can be used. The simplest is to consider 
that the same drug concentration in total intake, diet 
and water, will produce the same effect in the gut. A 
second simple method is to translate the daily intake 
per kg of metabolic body weight (i.e., BW to the 
power 0.72). These two simpleminded approaches 
lead to similar values when mouse data are 
extrapolated to humans (1). A third and more 
sophisticated approach requires extra experimental 
data. Let us assume that the bacteria have the same 
reaction to the drug in vivo, independent of the host 
(i.e., human or mouse). Therefore, the No Microbial 
Effect Concentration (NoMEC) should be identical 
inside the gut of mice and men. To extrapolate from 
mice to humans, the "dilution factor" between the 
mouth and the large bowel must be measured in both 
species. The Mouse Cecal Concentration (MCC) 
resulting from a given Mouse Intake (MI) and the 
Human Fecal Concentration (HFC) resulting from a 
given Human Intake (HI) should be measured.  
In mice, NoMEC (µg/g) = NoMEL (g/kg BW) x 
MCC (µg/g) / MI (g/kg BW)  
In men,  NoMEC (µg/g) = ADI   (g/kg BW) x HFC 
(µg/g) / HI (g/kg BW)
Because  human NoMEC = mouse NoMEC  
 ADI x HFC / HI = NoMEL x MCC / MI  
 ADI = NoMEL  x MCC/MI x HI/HFC
If the human "dilution factor" could not be measured 
in volunteers, it should be estimated. The fecal 
concentration of a non-absorbed agent equals the 
daily intake divided by the daily fecal weight. 
Absorption and metabolism must be accounted for by 
estimated percentages. The human dilution factor 
might thus be estimated by the following formula:  
HFC/HI = % Unabsorbed x % Unchanged x 60 (kg 
BW) / 0.15 (kg feces)
I think that there is no need to add a safety factor, 
because (i) the effect is not a true disease, (ii) it is 
measured in the target species (human bacteria), and 
(iii) the model system is very sensitive. Other authors 
think that a safety factor must be included in the 
calculation, to account for inter-individual variability.
Advantages of HFA mice over humans and 
chemostats
- Why are HFA mice studies better than human 
studies?
 A mouse study is less expensive than a 
human trial. Mice are easy to handle, and their flora 
is "normalized" at the start of the study (all mice are 
dosed with the same flora). No contamination or 
cross-contamination occurs during the trial (bacteria 
or drug do not cross the isolator). Mice may be dosed 
with drugs not allowed for human use, or challenged 
with pathogenic bacteria. In addition, mice's food 
composition is stable. A study with human volunteers 
is more difficult to control and can be unethical. 
 Day-to-day variations in resistance levels are 
observed in HFA mice, but are smaller than in 
humans (7). A low baseline of resistant organisms 
can be obtained by selecting human donors. These 
features make HFA mice a better controlled system 
than human volunteers (Table 1). When comparing 
the sensitivity of HFA mice and humans to the effect 
of low doses of tetracycline or ampicilline (7) on the 
proportion of drug resistant E.coli, it is concluded 
that the mouse model may be slightly more sensitive 
than the human model (Table 2). 
- Why are HFA mice studies better than chemostats 
studies? 
 Mice are easier to handle than chemostats 
(they self-regulate temperature, pH, nutrients). One 
mouse is less expensive than one chemostat, 
accordingly, 20 to 30 "experimental units" may be 
handled simultaneously. Therefore, in contrast with 
chemostat study, the sample size in HFA mice study 
is larger than one. However, data independence is not 
perfect since cross-contamination may occur within a 
cage and/or within an isolator, but not between 
isolators. The same kind of contamination can also 
occur in chemostats, and we do not know data 
showing that the composition of the flora remains the 
same after its transfer from the human gut to a 
chemostat.  
Mice are live animals and provide a natural 
environment to the bacteria. This environment 
supports the growth of "fastidious" bacteria, e.g., 
Clostridium difficile, which is not always the case 
with chemostats (3). The mouse model also provides 
(i) day-to-day variations in drug and nutrients levels 
in the gut ("feast and famine cycles"), (ii) ecological 
niches, i.e., colonic crypts and particles like fibers or 
cells from the mucosa (iii) semi-solid stools and a 
large mucosal surface for adhesion, which is a major 
determinant of the dynamic of resistance plasmid that 
is not reproduced in chemostats (9,10,11), and (iv) a 
gradient of endogenous nutrients like mucins, shed 
cells, bile acids, fibers, and metabolites. These 
features make the HFA mouse a more relevant model 
than the chemostat (Table 3). Moreover, the 
chemostat model appears to be much less sensitive to 
tetracycline effect than the human model (Table 2).
Advantages of humans and chemostats over HFA 
mice  
- Why are human studies better than HFA mice 
studies?
 Humans harbor human flora. Some human 
bacteria may disappear when the human flora is 
transferred into the mouse intestine (e.g., lactobacilli, 
bifidobacteria) (12). The ecology of the colonic flora 
may be different in mice and humans, because of the 
smaller volume and areas. There are also chemical 
differences in proteins, mucins, blood groups, bile 
acids, and other endogenous compounds between 
mice and humans. 
All people are different; therefore, a human trial can 
reflect the variability of human flora. This variability 
does not exist when the HFA mice are given the 
same (pool of) human flora(s). Volunteers leave a 
real life situation, which means many bacterial 
contaminations (13). In people, a drug treatment may 
boost new plasmids that enter the gut at random. 
However, HFA mice could also be given bacterial 
contaminants, like plasmid-bearing strains or 
pathogen challenges.  
The fate of drugs may not be the same in mice and 
men: absorption, excretion in the bile, change from 
the parent drug to inactive metabolites. Some 
differences could be accounted for by measuring the 
true "dilution factor" in both mice and men (see 
above). However, in the human model, the NoMEL 
in humans can directly be used as an ADI with no 
extrapolation needed. These human trials features 
make them the "gold standard" (Table 1). 
- Why are chemostats studies better than HFA mice 
studies?
 Today, more laboratories can handle a 
chemostat than germ-free mice (a chemostat is less 
expensive to set up than a germ-free facility, it 
requires less room, and technology is easier to learn). 
Each mouse fecal pellet is large enough for microbial 
counts. However, biochemical assays require large 
samples, obtained by pooling fecal samples from 
several mice, which reduces statistical power. 
 Sequential chemostat studies may give 
identical results, provided the same "starter" flora is 
used and kept deep-frozen. The same frozen "starter" 
can also be used to inoculate germ-free mice, 
although this has not yet been done. However, when 
different floras are used to inoculate a chemostat, 
different results are obtained, like in HFA mice 
studies (14). 
HFA mice studies sometimes yield discrepant or 
inconsistent results. For example, a drug can show an 
effect in male but not in female mice. The source of 
these discrepancies is not known, but may reflect the 
variability of the biological response. Mice may fight 
badly (notably male mice), escape from the cage and 
make a hole in the isolator, die, or be constipated. 
These problems do not exist in chemostats; thus they 
are better controlled systems than HFA mice (Table 
3). 
Conclusions:
 Human volunteers trials are clearly the most 
relevant studies to set microbio logical ADI: Data 
may be used directly and they may be considered as 
the "gold standard" (7,15). However, they human 
trials are very expensive and unethical. Thus, 
regulation agencies and industrial firms need other 
models of human intestinal microflora to assess the 
effect of antimicrobial residues. Chemostats with the 
continuous flow culture of a human flora are 
controlled systems, where the effect of antibiotic can 
easily be tested. The complex microflora stabilizes in 
the chemostat, and large samples may be taken for 
biochemical analysis. However, chemostats lack 
many features of living systems, and ADI calculated 
from chemostats studies are far from human studies 
results, at least for tetracycline. HFA mice trials are 
less expensive and more ethical to use, and can be 
better controlled than human trials. Compared with 
chemostats they provide true living ecological 
environment to the gut flora. Finally, the tetracycline 
ADI derived from HFA mice studies (7,12) is close 
to the ADI directly obtained in human volunteers 
(15). 
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Table 1: Respective benefits of HFA mice and human volunteers to assess the effect of antimicrobial 
residues on human gut flora. 
HFA mice benefits    Human volunteers benefits
- less expensive     - true human flora 
- easier to handle    - large human gut 
- one flora, many mice    - individual variability 
- no contamination     - real contaminations a
- controlled diet    - real diet (variable) b
- smaller variability    - human bile, mucus... 
- low baseline resistance 
=> sensitive system 
- any drug     - true human drug metabolism c
- pathogen challenge    - no calculation or extrapolation  
=> More ethical     is needed to set ADI 
Better Controlled    "Gold standard"
Notes to Table 1.
a- The HFA mice model can be improved by introducing on purpose plasmid bearing strains in the isolator, to 
mimic human contaminations. 
b- The HFA mice model can be improved by feeding mice with various human foods. 
c- Data from the HFA mice model should be corrected with measured "dilution factor" (see text). 
Table 2. Comparison of Acceptable Daily Intake (ADI) for human beings, extrapolated from three 
experimental models: chemostat, HFA mice and human volunteers. Results show the lowest tetracycline 
level that increases tetracycline resistance in the human gut flora. 
Reference   Model   Lowest tested level     ADIb      
        with an effecta      mg/d
Carman (3)  chemostat  15 µg/ml medium  < 150.c
Corpet (7)   HFA mice  0.5 ppm in water  < 0.75d
Guyomard (12) HFA mice  1 ppm in water   < 1.5d
Tancrede (15)  volunteers  2 mg/person/de   < 2.0 
Notes to Table 2:
a- Minimum tetracycline dose leading to significant increase in the proportion of drug-resistant E. coli in the 
human gut flora. In HFA mice and humans, the no effect level was not determined. In the chemostat study, 1.5 
µg/ml was a no effect level. 
b- Maximum extrapolated ADI for a person of 60 kg BW. Derived only for comparisons, and should not be used 
as such for regulations. 
c- 15 µg/d matches 100 "FDA-ADI", that is 100 times 1.5 mg/person/d (3). 
d- Extrapolation was done according to Cerniglia and Kotarsky (2). Calculations with different methods give 
similar results: ADIs derived from HFA mice studies are in the range 0.5-2 mg/person/d (1,7). 
e- Tancrede's data (15) show that the proportion of resistant E.coli increased in each of the six volunteers given 2 
mg/d oxytetracycline for seven days, compared with control period (median increase: 30 times, range: 2-3200). In 
contrast with Tancrede's conclusion, this increase was significant at p=0.05 (1) 
Table 3: Respective benefits of HFA mice and chemostat to assess the effect of antimicrobial residues on 
human gut flora. 
HFA Mice Benefits    Chemostat Benefits
- easier to handle     - more labs can do it 
- less expensive: many mice 
- live animals :     - better controlled 
  > mucus, bile, cells    - larger samplesa  
  > drug variations    - always same starter florab
  > crypts, niches     
- male and female    - less experimental incidents 
- results closer to humans'c    - more ethical 
More Relevant    Better Controlled
Notes to Table 3.
a- Large samples for biochemistry could be obtained from HFA mice, by pooling fecal samples, or taking cecal 
samples after sacrifice. An alternative might be the use of HFA rats. 
b- A frozen "starter" flora could be used to inoculate germfree mice, exactly as done in chemostats. It would 
"normalize" the flora, but the barrier effect was weaker with a frozen flora than with a fresh flora (unpublished 
results, Corpet 92). 
c- See Table 2. 
